Investor Materials
Bala Ingredients is pioneering a neuromodulating ingredient engineered to replace alcohol (ethanol) across the global beverage industry. Our flagship ingredient, Serendial, delivers the connection and relaxation people seek from drinking, without the toxicity, damage, or hangovers.
Download our Executive Summary or Pitch Deck to explore our business model, funding structure, and market strategy.
To obtain a copy of our Scientific White Paper, please submit an Access Request. The white paper contains deeper technical insight into Serendial’s molecular structure, biosynthetic refinement, and evidence supporting its safety and function.
Bala Ingredients is engineering the future of alcohol.
Frequently Asked Questions
Serendial is a designed neuromodulating ingredient that replicates the effects people seek from drinking alcohol—connection and relaxation—without the toxicity, hangovers, or long‑term damage associated with ethanol. It’s built as a B2B ingredient for beverages, not a consumer supplement or “feel‑good” placebo.
Most “non‑alcoholic” or functional beverages remove alcohol and add botanicals, nootropics, or GABA blends that can shift mood but rarely feel like a true replacement. Serendial is engineered specifically to reproduce alcohol‑like chemistry in a controlled way, not just add flavor or light relaxation, which is why we position it as an alcohol replacement rather than a mood enhancer.
Serendial is being developed to engage the brain pathways involved in social relaxation without the broad, system‑wide toxicity of ethanol, which damages organs and disrupts cognition over time. We design dose, onset, and duration to be predictable and self‑limiting, and we’re running toxicology and safety studies to confirm non‑addictive, food‑grade use before any large‑scale launch.
The core molecule is roughly 95% complete, and our current pre‑seed round funds final optimization and Self Affirmed GRAS‑aligned safety work. We’ve already filed a provisional utility patent and secured signed LOIs totaling around $10M in projected revenue, and our roadmap targets Serendial v1 entering controlled commercial pilots after this phase.
Our LOIs are non‑binding commercial expressions of interest from beverage partners outlining intended volumes and use of Serendial in future products, contingent on successful development, safety, and regulatory milestones. They signal real, early demand from partners who are ready to pilot once the molecule is cleared for use.
Bala is building an ingredient platform, not a standalone drink brand. We supply Serendial to established and emerging beverage companies through licensing and supply agreements, letting them integrate it into their own products and leverage their existing brands, distribution, and retail relationships.
We are pursuing a food‑grade pathway (Self Affirmed GRAS) and structuring our studies, labeling expectations, and partner guidelines around responsible use from day one. We’re also very aware of public perception risk, so we position Serendial as a safer replacement for an existing social experience, not a “drug,” and we plan to work only with partners who align on those guardrails.
NO!
Serendial is being developed as a food‑grade beverage ingredient, not as a pharmaceutical drug. We are structuring the molecule, dosing, and studies around a Self Affirmed GRAS and CPG framework so it can be used in beverages rather than through a prescription route, which can significantly reduce regulatory timelines compared with a full drug development program.
This pre‑seed round funds final molecular refinement, IP, and safety work to get Serendial version 1 ready for controlled pilots with existing LOI partners. From there, the focus is on converting pilots into recurring ingredient supply agreements, scaling manufacturing, and expanding the partner base as we validate performance, safety, and consumer adoption in‑market.